Replies to post #209501 on Biotech Values

[DewDiligence]

AMGN—Weekly Kyprolis—at 30% higher cumulative weekly dose—shows statsig superior PFS and comparable safety to (standard) semi-weekly Kyprolis in second-line MM:

https://www.prnewswire.com/news-releases/phase-3-arrow-study-of-once-weekly-kyprolis-carfilzomib-regimen-meets-primary-endpoint-of-progression-free-survival-in-relapsed-and-refractory-multiple-myeloma-patients-300541392.html